Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDAMarket Beat·Sep 3 at 02:01 AMANVS-6.47%
ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-yearQuartr·Aug 14 at 08:32 PMANVS-6.47%
Annovis Provides Corporate Updates and Second Quarter 2026 Financial ResultsUnusual Whales·Aug 14 at 12:01 PMANVS-6.47%
Annovis Bio completes enrollment in Phase 3 early Alzheimer’s trial of buntanetapPUBT·Jul 10 at 10:04 AMANVS-6.47%
Annovis Bio reaches full enrollment in Phase 3 early Alzheimer’s trial of buntanetapPUBT·Jul 7 at 11:02 AMANVS-6.47%
Annovis Bio Launches ~$15 Million Stock-and-Warrant Offering Underwritten by Canaccord GenuityTradingView·May 20 at 08:23 PMANVS-6.47%
Annovis Bio Announces Offering Of Shares And Warrants To Advance Buntanetap In AD; Stock Downnasdaq·May 20 at 09:45 AMANVS-6.47%
